SCHEMBL5451688

SCHEMBL5451688

CCOC(=O)C(P(=O)(O)OCC)(P(=O)(O)OCC)P(=O)(O)OCC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PPARD Q03181 1/20 0.38
ALDH1A1 P00352 2/20 0.37
TSHR P16473 2/20 0.37
PKM P14618 2/20 0.36
KDM4E B2RXH2 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
LMNA P02545 1/20 0.36
HSD17B10 Q99714 1/20 0.36
MAPT P10636 1/20 0.36
CYP4F2 P78329 2/20 0.35
CYP4A11 Q02928 2/20 0.35
THRB P10828 1/20 0.35
CYP3A4 P08684 2/20 0.35
ABCB11 O95342 1/20 0.35
CYP1A2 P05177 1/20 0.35
HTR2A P28223 1/20 0.35
PMP22 Q01453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL411532 0.82 CYP4F2 (0.38) PPARDALDH1A1TSHRPKMKDM4E
SCHEMBL3626070 0.81 PKM (0.36) PPARDALDH1A1TSHRPKMKDM4E
SCHEMBL5451691 0.80 MAPT (0.37) PPARDALDH1A1TSHRPKMKDM4E
SCHEMBL7122559 0.80 ALDH1A1 (0.34) ALDH1A1TSHRPKMKDM4EMEN1
SCHEMBL10590584 0.80 PPARD (0.35) PPARDALDH1A1TSHRPKMKDM4E
SCHEMBL98777 0.78 TSHR (0.40) TP53TDP1PPARDTSHRCYP3A4
SCHEMBL7741220 0.77 PPARD (0.41) PPARDALDH1A1TSHRPKMKDM4E
SCHEMBL2679555 0.77 PPARD (0.39) TP53TDP1PPARDTSHRMEN1
SCHEMBL7775440 0.75 PPARD (0.38) TP53TDP1PPARDTSHRCYP3A4
SCHEMBL6623038 0.75 PPARD (0.38) TP53TDP1PPARDTSHRCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 US disclosed
EP-4269404-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-11-01 EP disclosed
EP-3240784-A2 INHIBITORS OF AKT KINASE BerGenBio ASA (NO) 2017-11-08 EP disclosed
US-9441161-B2 Liquid crystal compound, liquid crystal composition and liquid crystal display device JNC CORPORATION (JP) 2016-09-13 US disclosed
WO-2016102672-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS BERGENBIO AS (NO) 2016-06-30 WO disclosed
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE JNC PETROCHEMICAL CORPORATION (JP) 2016-02-04 US disclosed
US-20070225269-A1 Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides SYNGENTA CROP PROTECTION, INC. 2007-09-27 US disclosed
EP-1732385-A1 USE OF (3-(1-(3-PHENYL-PROPENYL)-PIPERIDIN-4-YL)-2,3-DIHYDRO-INDOL-1-YL)-(PYRIDIN-4-YL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES Syngenta Participations AG (CH) 2006-12-20 EP disclosed
WO-2005058035-A1 USE OF (3-(1-(3-PHENYL-PROPENYL)-PIPERIDIN-4-YL)-2,3-DIHYDRO-INDOL-1-YL)-(PYRIDIN-4-YL)-METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES SYNGENTA PARTICIPATIONS AG (CH) 2005-06-30 WO disclosed
US-5559233-A 3-/P-PHENYLBENZYL/IMIDAZOLONES AND PYRIMIDONES SANOFI (FR) 1996-09-24 US disclosed
US-5352788-A Angiotensin antagonist ELF SANOFI (FR) 1994-10-04 US disclosed
US-5270317-A N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present ELF SANOFI (FR) 1993-12-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160032187-A1 LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE OCIAD1, OCIAD2, PIEZO1 TP53 3862/4885TDP1 1275/4885PPARD 4628/4885
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF KHK, GCK, HK1 TP53 4472/4885TDP1 2304/4885PPARD 885/4885
US-20070225269-A1 Use of (3-(1-(3-Phenyl-Propenyl)-Piperidin-4-Yl)-2,3-Dihydro-Indol-1-Yl)-(Pyridin-4-Yl)-Methanonone Derivatives and Related Compounds as Insecticides CHRM1, NPY1R, MRM1 TP53 4685/4885TDP1 479/4885PPARD 2670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.